MW-C1 / Mabwell (Shanghai) Biosci - LARVOL DELTA

MW-C1, a novel CLDN1-targeting ADC demonstrates compelling anti-tumor efficacy and favorable safety profile in preclinical studies (AACR 2025) - "MW-C1 demonstrated potent anti-tumor efficacy and a favorable safety profile, highlighting its potential as a transformative therapeutic candidate for the treatment of CLDN1-overexpressing malignancies."

Preclinical • Cervical Cancer • Head and Neck Cancer • Hepatocellular Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • CLDN1